Rivaroxaban as thromboprophylaxis improves clinical outcomes after COVID-19 hospitalization
Johnson booster 85% effective against Omicron: S.Africa study
30 December 2021Study uncovers unique stem cell trajectory in lungs damaged by COVID-19 and pulmonary fibrosis
30 December 2021Rivaroxaban as thromboprophylaxis improves clinical outcomes after COVID-19 hospitalization
For patients at high risk for venous thromboembolism (VTE) discharged after COVID-19 hospitalization, thromboprophylaxis with rivaroxaban is associated with improved clinical outcomes, according to a study published online Dec. 15 in The Lancet.
